|
US6348581B1
(en)
*
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
|
CN1064052C
(zh)
*
|
1997-09-29 |
2001-04-04 |
中国科学院微生物研究所 |
甲状旁腺素相关蛋白人源化抗体及其制备方法
|
|
AU2444899A
(en)
*
|
1998-01-22 |
1999-08-09 |
Astrazeneca Ab |
Pharmaceutical formulation comprising an antibody and a citrate buffer
|
|
GB9906233D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Univ Newcastle |
Bone formation
|
|
WO2002034929A2
(fr)
*
|
2000-10-20 |
2002-05-02 |
Whitehead Institute For Biomedical Research |
Vecteurs d'expression et leurs utilisations
|
|
AU2003221118A1
(en)
*
|
2002-03-22 |
2003-10-08 |
Bipha Corporation |
Immunoglobulin/hydrophilic peptide complexes
|
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
|
GB0302740D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Axis Shield Asa |
Assay
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
MXPA06012187A
(es)
*
|
2004-04-22 |
2007-03-28 |
Agensys Inc |
Anticuerpos y moleculas derivadas de estas que se enlazan a las proteinas steap-1.
|
|
WO2006137354A1
(fr)
*
|
2005-06-21 |
2006-12-28 |
Medical & Biological Laboratories Co., Ltd. |
Anticorps avec effet inhibiteur sur la formation de fibrilles amyloïdes
|
|
KR100740201B1
(ko)
*
|
2005-10-21 |
2007-07-18 |
삼성전자주식회사 |
듀얼 전송 스트림 생성 장치 및 그 방법
|
|
US20090074720A1
(en)
*
|
2005-10-28 |
2009-03-19 |
Sabbadini Roger A |
Methods for decreasing immune response and treating immune conditions
|
|
US20080213274A1
(en)
*
|
2005-10-28 |
2008-09-04 |
Sabbadini Roger A |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
|
|
WO2007125089A2
(fr)
*
|
2006-04-28 |
2007-11-08 |
ETH Zürich |
Anticorps pour la détection de bacillus anthracis et vaccin contre des infections à b. anthracis
|
|
US7862812B2
(en)
*
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
|
AU2007269714A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
|
PT2087002E
(pt)
*
|
2006-10-27 |
2014-11-26 |
Lpath Inc |
Composições e métodos para a ligação de esfingosina-1- fosfato
|
|
US8444970B2
(en)
*
|
2006-10-27 |
2013-05-21 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
|
WO2008150841A1
(fr)
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions et procédés pour lier de l'acide lysophosphatidique
|
|
JP2010535503A
(ja)
|
2007-08-10 |
2010-11-25 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ（エー＊エスティーエーアール） |
癌の診断および治療のためのｖｈｚ
|
|
EP2201040A1
(fr)
*
|
2007-09-24 |
2010-06-30 |
Vanderbilt University |
Anticorps monoclonaux au virus respiratoire syncytial et leurs utilisations
|
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
|
JP5756014B2
(ja)
*
|
2008-08-08 |
2015-07-29 |
エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） |
がんの診断および治療のためのｖｈｚ
|
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
|
WO2010062960A2
(fr)
|
2008-11-26 |
2010-06-03 |
Cedars-Sinai Medical Center |
Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire
|
|
CA2745111A1
(fr)
|
2008-12-03 |
2010-06-10 |
Research Development Foundation |
Modulation de l'angiogenese a mediation par olfml-3
|
|
JP2012511026A
(ja)
*
|
2008-12-05 |
2012-05-17 |
エルパス・インコーポレイテッド |
抗脂抗体結晶構造を用いた抗体設計
|
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
EP2400981A4
(fr)
*
|
2009-02-26 |
2013-02-27 |
Lpath Inc |
Conception d'anticorps humanisé anti-facteur d'activation plaquettaire à l'aide de modèles d'anticorps anti-lipide
|
|
EP2419446A4
(fr)
*
|
2009-04-17 |
2013-01-23 |
Lpath Inc |
Compositions d'anticorps humanisés et procédés de liaison d'acide lysophosphatidique
|
|
US8859736B2
(en)
|
2010-02-19 |
2014-10-14 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
|
SI2654781T1
(sl)
|
2010-12-21 |
2018-10-30 |
Selexys Pharmaceuticals Corporation |
Protitelesa proti P-selektinu in postopki za njihovo uporabo in identifikacijo
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
US9555108B2
(en)
|
2011-03-24 |
2017-01-31 |
Texas Tech University System |
TCR mimic antibodies as vascular targeting tools
|
|
CA2840175C
(fr)
|
2011-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Agents se liant a l'integrine alpha-2 et leur utilisation pour inhiber la proliferation des cellules cancereuses
|
|
EP2739310B1
(fr)
|
2011-08-05 |
2018-04-18 |
Research Development Foundation |
Procédés et compositions améliorés pour la modulation de l'angiogenèse médiée par olfml3
|
|
EP3718556A3
(fr)
|
2012-08-31 |
2020-12-30 |
University Of Virginia Patent Foundation |
Peptides cibles pour l'immunothérapie et le diagnostic
|
|
EP4088737A3
(fr)
|
2012-09-05 |
2023-02-08 |
University Of Virginia Patent Foundation |
Peptides cibles pour la thérapie et les diagnostics du cancer colorectal
|
|
AU2013334583B2
(en)
|
2012-10-24 |
2018-09-13 |
Research Development Foundation |
JAM-C antibodies and methods for treatment of cancer
|
|
WO2014093855A1
(fr)
|
2012-12-13 |
2014-06-19 |
University Of Virginia Patent Foundation |
Peptides cibles pour une thérapie et le diagnostic du cancer de l'ovaire
|
|
KR20210157418A
(ko)
|
2013-03-27 |
2021-12-28 |
세다르스-신나이 메디칼 센터 |
Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
|
|
EP4105236A1
(fr)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anticorps contre tl1a (tnfsf15) pour le traitement des maladies inflammatoires de l'intestin
|
|
WO2015027120A1
(fr)
|
2013-08-21 |
2015-02-26 |
Jiang Jean X |
Compositions et méthodes de ciblage de semi-canaux de connexine
|
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
AU2016365318B2
(en)
|
2015-12-02 |
2024-04-18 |
Board Of Regents, The University Of Texas System |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
|
US10889637B2
(en)
|
2016-02-26 |
2021-01-12 |
The Board Of Regents Of The University Of Texas System |
Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
|
|
CN109462996A
(zh)
|
2016-03-17 |
2019-03-12 |
西达-赛奈医疗中心 |
通过rnaset2诊断炎性肠病的方法
|
|
JP7241541B2
(ja)
|
2016-03-29 |
2023-03-17 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ－ｌ１に特異的な二重機能抗体およびその使用方法
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
CN109715666B
(zh)
|
2016-07-20 |
2023-02-21 |
斯特库比股份有限公司 |
癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
|
|
SG11201903737PA
(en)
|
2016-10-26 |
2019-05-30 |
Cedars Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
|
SG11201909751TA
(en)
|
2017-05-12 |
2019-11-28 |
Augusta University Research Institute Inc |
Human alpha fetoprotein-specific t cell receptors and uses thereof
|
|
AU2018277545B2
(en)
|
2017-05-31 |
2025-05-15 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
|
EP3625254B1
(fr)
|
2017-07-31 |
2023-12-13 |
F. Hoffmann-La Roche AG |
Procédé d'humanisation fondé sur une structure tridimensionnelle
|
|
GB2581619A
(en)
|
2017-09-15 |
2020-08-26 |
Univ California |
Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
|
|
CA3081548A1
(fr)
|
2017-09-26 |
2019-04-04 |
The Regents Of The University Of California |
Compositions et methodes de traitement du cancer
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
EP3765517A1
(fr)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Molécules multifonctionnelles se liant à calréticuline et utilisations associees
|
|
WO2019195561A2
(fr)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Agents anti-tétraspanine 33 et compositions et procédés pour la fabrication et l'utilisation de ces agents
|
|
US20210070871A1
(en)
|
2018-04-25 |
2021-03-11 |
Prometheus Biosciences, Inc. |
Optimized anti-tl1a antibodies
|
|
WO2020010250A2
(fr)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Molécules d'anticorps anti-tcr et leurs utilisations
|
|
EP3856343A1
(fr)
|
2018-09-25 |
2021-08-04 |
Biolegend, Inc. |
Agents anti-tlr9 et compositions et procédés pour les préparer et les utiliser
|
|
EP3863671A4
(fr)
|
2018-10-12 |
2022-07-20 |
Jumaa-Weinacht, Hassan |
Anticorps monoclonal pour le traitement de la leucémie lymphoblastique aiguë
|
|
JP2022524175A
(ja)
|
2018-11-02 |
2022-04-28 |
オクラホマ メディカル リサーチ ファウンデーション |
Ｅｌｔｄ１に対するモノクローナル抗体及びその使用
|
|
AU2020224680B2
(en)
|
2019-02-21 |
2025-06-19 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
CN114126714A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
AU2020224154B2
(en)
|
2019-02-21 |
2025-05-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
KR20220088428A
(ko)
|
2019-09-26 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
|
|
CN114829404B
(zh)
|
2019-10-09 |
2025-09-09 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
|
CN114901311A
(zh)
|
2019-10-24 |
2022-08-12 |
普罗米修斯生物科学公司 |
Tnf样配体1a（tl1a）的人源化抗体及其用途
|
|
EP4084821A4
(fr)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Molécules multifonctionnelles se liant à cd33 et utilisations associées
|
|
CA3166629A1
(fr)
*
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Molecules d'anticorps anti-tcr et leurs utilisations
|
|
EP4090681A1
(fr)
|
2020-01-17 |
2022-11-23 |
Biolegend, Inc. |
Agents anti-tlr7 et compositions et procédés de fabrication et d'utilisation de ceux-ci
|
|
CA3168337A1
(fr)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Procedes d'expansion de lymphocytes infiltrant les tumeurs et leur utilisation
|
|
WO2021217085A1
(fr)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
CN116249718A
(zh)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
结合至钙网蛋白的多功能性分子及其用途
|
|
WO2022093641A1
(fr)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
|
|
WO2022093640A1
(fr)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci
|
|
WO2022119955A1
(fr)
|
2020-12-01 |
2022-06-09 |
The Johns Hopkins University |
Méthodes et matériaux pour traiter des cancers des lymphocytes t
|
|
CA3214757A1
(fr)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Molecules multifonctionnelles se liant au tcr et leurs utilisations
|
|
EP4558523A1
(fr)
|
2022-07-19 |
2025-05-28 |
Biolegend, Inc. |
Anticorps anti-cd157, fragments de liaison à l'antigène de ceux-ci, compositions, procédés de fabrication et d'utilisation de ceux-ci
|
|
CN119968395A
(zh)
|
2022-08-18 |
2025-05-09 |
百进生物科技公司 |
抗axl抗体、其抗原结合片段及其制备和使用方法
|
|
WO2024243217A1
(fr)
|
2023-05-25 |
2024-11-28 |
BioLegend, Inc. |
Anticorps liant ceacam6 et fragments de liaison à l'antigène de ceux-ci
|
|
WO2025036848A1
(fr)
|
2023-08-11 |
2025-02-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anticorps anti-muc16 et utilisations
|
|
WO2025072313A1
(fr)
|
2023-09-27 |
2025-04-03 |
BioLegend, Inc. |
Anticorps anti-gpc4
|
|
TW202523694A
(zh)
|
2023-11-17 |
2025-06-16 |
中國大陸商上海藥明生物技術有限公司 |
抗muc16抗體及其用途
|